Chiome Bioscience Inc

Chiome Bioscience Inc. has a market price of 97.0 JPY and a market capitalization of 7,186,222,787 JPY, indicating a relatively high valuation compared to its tangible book value. The company's price-to-book ratio is 6.4, and its price-to-tangible-book ratio is also 6.4, suggesting that the market is valuing the company significantly above its book value. The company's liquidity position is strong, with a current ratio of 4.13, indicating that it has sufficient current assets to cover its current liabilities. The company's profitability is currently negative, with a return on equity of -0.8759 and a return on assets of -0.5689, indicating that it is not generating returns for its shareholders or assets. The company's operating income is -970,186,000 JPY, and its net income is -982,779,000 JPY, reflecting significant losses. The debt-to-equity ratio is 0.23, indicating a relatively low level of leverage. Chiome Bioscience Inc. operates in two business segments: Drug Discovery and Drug Discovery Support. The Drug Discovery segment is focused on the research and development of specific antibodies based on new antigens and mechanisms, while the Drug Discovery Support segment is engaged in the development of lead antibodies for therapeutic drugs in collaboration with pharmaceutical companies in Japan and overseas. The company's geographic exposure is primarily in Japan, with no significant revenue concentration in other regions. The company's growth trajectory is currently negative, with a significant decline in revenue and profitability. The company's operating cash flow is -935,989,000 JPY, and its free cash flow is -1,019,119,000 JPY, indicating that it is not generating positive cash flows from its operations. The company's capital expenditure is -40,080,000 JPY, suggesting that it is not investing heavily in new projects or infrastructure. The company's risk assessment indicates a low level of liquidity and dilution risk. There are no immediate filing-based liquidity or dilution flags, and the company's debt-to-equity ratio is relatively low. The company's liquidity position is strong, with a current ratio of 4.13, indicating that it has sufficient current assets to cover its current liabilities. The company's dilution risk is also low, with no significant dilution potential in the near term. Recent events and filings do not indicate any significant changes in the company's financial position or strategic direction. The company continues to focus on its research and development activities in the biotechnology and medical research sectors. There are no immediate regulatory or geopolitical risks that are expected to impact the company's operations or financial performance.